Evidence map›Paper›PMID 30688265›Full record

ArticleNeural regeneration research2019

Yu-Min Xu, Xin-Chen Wang, Ting-Ting Xu, Hong-Ying Li, Shang-Yan Hei, Na-Chuan Luo, Hong Wang, Wei Zhao, Shu-Huan Fang, Yun-Bo Chen and 5 more

Open access · goldAbstract read
In one paragraph

Article in Neural regeneration research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Anti-Amnesic Effect ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Therapeutic Potential of Active Components fromJournal of pharmacopuncture · 2022
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Yu-Min XuInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province; First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan Province, China.
Xin-Chen WangSchool of Food and Pharmaceutical Engineering, Zhaoqing University, Zhaoqing, Guangdong Province, China.
Ting-Ting XuInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China.
Hong-Ying LiInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China.
Shang-Yan HeiInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China.
Na-Chuan LuoInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China.
Hong WangInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China.
Wei ZhaoInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China.
Shu-Huan FangInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China.
Yun-Bo ChenInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China.
Li GuanInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China.
Yong-Qi FangFirst Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China.
Shi-Jie ZhangInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province; Department of Neurology, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Qi WangInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine; Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong Province, China.
Wei-Xiong LiangInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine; Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong Province, China.
Guangzhou University of Chinese Medicine · CNQi2 · USFirst Affiliated Hospital of Guangzhou University of Chinese Medicine · CNFirst Affiliated Hospital of Henan University · CNGuangdong Provincial Hospital of Traditional Chinese Medicine · CNZhaoqing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kai Xin San (KXS, containing ginseng, hoelen, polygala, and acorus), a traditional Chinese herbal compound, has been found to regulate cognitive dysfunction; however, its mechanism of action is still unclear. In this study, 72 specific-pathogen-free male Kunming mice aged 8 weeks were randomly divided into a vehicle control group, scopolamine group, low-dose KXS group, moderate-dose KXS group, high-dose KXS group, and positive control group. Except for the vehicle control group and scopolamine groups (which received physiological saline), the doses of KXS (0.7, 1.4 and 2.8 g/kg per day) and donepezil (3 mg/kg per day) were gastrointestinally administered once daily for 2 weeks. On day 8 after intragastric treatment, the behavioral tests were carried out. Scopolamine group and intervention groups received scopolamine 3 mg/kg per day through intraperitoneal injection. The effects of KXS on spatial learning and memory, pathological changes of brain tissue, expression of apoptosis factors, oxidative stress injury factors, synapse-associated protein, and cholinergic neurotransmitter were measured. The results confirmed the following. (1) KXS shortened the escape latency and increased residence time in the target quadrant and the number of platform crossings in the Morris water maze. (2) KXS increased the percentage of alternations between the labyrinth arms in the mice of KXS groups in the Y-maze. (3) Nissl and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining revealed that KXS promoted the production of Nissl bodies and inhibited the formation of apoptotic bodies. (4) Western blot assay showed that KXS up-regulated the expression of anti-apoptotic protein Bcl-2 and inhibited the expression of pro-apoptotic protein Bax. KXS up-regulated the expression of postsynaptic density 95, synaptophysin, and brain-derived neurotrophic factor in the cerebral cortex and hippocampus. (5) KXS increased the level and activity of choline acetyltransferase, acetylcholine, superoxide dismutase, and glutathione peroxidase, and reduced the level and activity of acetyl cholinesterase, reactive oxygen species, and malondialdehyde through acting on the cholinergic system and reducing oxidative stress damage. These results indicate that KXS plays a neuroprotective role and improves cognitive function through reducing apoptosis and oxidative stress, and regulating synapse-associated protein and cholinergic neurotransmitters.

Indexed as

apoptosischolinergic system dysfunctioncognitive dysfunctiondonepezilKai Xin Sanneural regenerationneuroprotectionoxidative stressscopolamine hydrobromidesynaptic dysfunction

Identifiers

PMID30688265
PMCPMC6375048
OpenAlexW2913593721

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.